Safer CAR Ts & world’s first TIL: BioCentury’s latest podcast

Plus: translational highlights and Sarepta’s path to a gene therapy approval 

Off switches and non-viral delivery technologies may be the solution to CAR T therapies’ most recent safety problem. On the latest BioCentury This Week podcast, BioCentury’s editors discuss alternative CAR T technologies already in development that avoid or reduce the risk of secondary malignancy.

The editors also discuss the world-first approval of a tumor-infiltrating lymphocyte (TIL) therapy from Iovance Biotherapeutics Inc. (NASDAQ:IOVA), highlights from BioCentury’s most recent survey of the translational literature in the Distillery, and the path to approval for Elevidys delandistrogene moxeparvovec, a gene therapy from  Sarepta Therapeutics Inc. (NASDAQ:SRPT) for Duchenne muscular dystrophy.

Join BioCentury, BayHelix and McKinsey March 4-6 in Singapore for the third East-West Biopharma Summit. For information on how to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact BioCentury at conferences@biocentury.com.